Drug intelligence / Profile preview

compound 451238

Development stage: Phase 2
Lead developer: Royal Marsden NHS Foundation Trust
Modality: Small Molecules
Administration: Unspecified (clinical Trials Do Not Specify Route)

Overview

Compound 451238 is a small molecule antineoplastic drug under investigation for the treatment of soft tissue sarcoma. It is being developed by Royal Marsden NHS Foundation Trust in collaboration with Merck KGaA. The precise mechanism of action has not been publicly defined, and it is considered a new molecular entity. Clinical development has reached Phase I/II trials, primarily targeting advanced or late-stage soft tissue sarcoma, including as combination therapy with radiotherapy[1][2][4].

Other names: compound 451238compound451238compound-451238

Beyond the preview

Go deeper on compound 451238.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 451238.

Explore the full profile